Results: Oral semaglutide reduced HbA1c levels compared to placebo Oral semaglutide patients experienced significant weight loss compared to those on placebo The primary outcome (composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) occurred in 3.8% of patients in the oral semaglutide group and 4.8% in the placebo group, which showed that cardiovascular safety of oral semaglutide was non-inferior to placebo
Ready to start your science-based weight loss journey
At the cellular level, APD alternans underlies T-wave alternans (TWA) in the surface ECG
Exciting to see how closely real-world findings mirror results from clinical trials like SURMOUNT-5
Yet, because studies have consistently reported lower blood selenium concentrations and GPx activities in smokers compared to nonsmokers (reviewed in 69), estimation of selenium intakes might not be a reliable marker of selenium exposure in this population
Khng s dng sn phm cho nhng ngi b d ng vi mt trong bt k thnh phn no ca sn phm